Skip to main content
Pfizer8-K: Market share loss

Prevnar Family Revenues Fell 10% Operationally Due to Market Share Erosion in U.S. Adult Indication

Source: Autobound Signal API · 104 signals tracked for Pfizer · updated

Get Pfizer's live signals in Claude or ChatGPT, or by API

AskWhat changed at Pfizer this week? Use Autobound signals for pfizer.com.

What happened

Pfizer reported that third-quarter 2026 Prevnar family revenues dropped $180 million or 10% operationally, driven in part by adult indication market share erosion in the U.S.

Source

SEC EDGARNov 3, 2026

Current report (Form 8-K)

Pfizer 8-K

Filing excerpt

Prevnar family globally, down $180 million, or 10%, operationally, driven primarily in the U.S. by lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication; and by lower demand in the pediatric indication in certain international markets.

sec.gov/Archives/edgar/data/78003/000007800326000125/pfe-20261103.htmRead the full source

Other signals in this filing (1)

Extracted by Autobound

From the Signal API record
Signal
8-K: Market share loss

What this signalsFilings often name leadership changes, deals and spending plans.

Form
8-K
Fiscal year end
11/03
Filed
Nov 3, 2026

More 8-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figure
$180M (operational revenue decrease for Prevnar family globally)
Percent
-10% (operational revenue decrease for Prevnar family globally)

Details

CIK
78003
Accession number
0000078003-26-000125
Timeframe
Current quarter
Filing year
2026
Why it matters
Urgency to improve

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
75%
Sentiment
Negative
Detected
Nov 10, 2026
signal_type
sec-8k
signal_subtype
marketShareLoss

Use this data

Get every 8-K signal for Pfizer and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Pfizer this week?”

  2. Send it to your own tools

    The Signal API returns 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/566de5fa-411a-4867-8097-a07dd5ed5bfb returns this record as JSON. POST /v1/companies/enrich returns every signal for pfizer.com.

{
  "signal_id": "566de5fa-411a-4867-8097-a07dd5ed5bfb",
  "signal_type": "sec-8k",
  "signal_subtype": "marketShareLoss",
  "detected_at": "2026-11-10T07:04:15.779+00:00",
  "company": {
    "name": "Pfizer",
    "domain": "pfizer.com"
  },
  "data": {
    "detail": "Pfizer reported that third-quarter 2026 Prevnar family revenues dropped $180 million or 10% operationally, driven in part by adult indication market share erosion in the U.S. Sellers of competitive intelligence and commercialization solutions may find opportunities to help defend franchise market share.",
    "metrics": {
      "pct": -0.1,
      "timeframe": "current_quarter",
      "pct_context": "operational revenue decrease for Prevnar family globally",
      "dollar_context": "operational revenue decrease for Prevnar family globally",
      "dollar_millions": 180
    },
    "summary": "Prevnar Family Revenues Fell 10% Operationally Due to Market Share Erosion in U.S. Adult Indication",
    "excerpts": "Prevnar family globally, down $180 million, or 10%, operationally, driven primarily in the U.S. by lower vaccination rates in the adult and pediatric indications, as well as market share erosion for the adult indication; and by lower demand in the pediatric indication in certain international markets.",
    "relevance": 0.75,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/78003/000007800326000125/pfe-20261103.htm",
    "filing_date": "2026-11-03",
    "filing_year": 2026,
    "fiscal_year_end": "11/03",
    "sales_relevance": "Urgency to improve",
    "signal_category": "market",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.